Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Nichi-Iko Pharmaceutical Co., Ltd.
- 1,570.00 JPY
- -7.00
- -0.44%
Japan
Jul 20, 2018Ticker
TKS(4541)Prev. close
1,577Market cap (JPY)
95,665MMarket cap (USD)
855.41MShares
60.66M
In the news
- China extends drug patents to 25 years May 16, 2018
- Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018
- Nichi-Iko to sell generics in Philippines, Singapore Sep 2, 2017
- Teva Takeda Pharma shooting for $916m in sales in 2017 Apr 22, 2017
- Japan's Sawai Pharma to buy US generics maker Apr 21, 2017 See more articles on Nichi-Iko Pharmaceutical Co., Ltd.
Business Summary
Nichi-Iko Pharmaceutical Co., Ltd. develops, manufactures, and markets generic pharmaceutical products. Its products are classified into Prescriptive and General Over-the-Counter (OTC) drugs. These products are used for the treatment of circulatory, digestive, respiratory, central and peripheral nervous systems problems. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.
Financial Highlights
| Mar 2018 | JPY | USD |
| Revenue | 164,717M | 1,486.18M |
| Gross Profit | 40,803M | 368.15M |
| Operating income | 13,200M | 119.09M |
| Income before tax | 9,067M | 81.80M |
| Net income | 8,069M | 72.80M |
| EBITDA | 22,179M | 200.11M |
| Diluted EPS | 142.92 | 1.28 |
| Dividends Per Share | 30 | 0.27 |
| Total Assets | 278,364M | 2,617.43M |
| Total liabilities | 190,819M | 1,794.25M |
| Total equity | 87,542M | 823.14M |
| Operating cash flow | 18,925M | 170.75M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 103,622M | 127,021M | 143,513M | 149,263M | 164,717M |
| Gross Profit | 39,449M | 46,876M | 53,313M | 37,611M | 40,803M |
| Operating income | 7,383M | 9,619M | 12,910M | 10,026M | 13,200M |
| Income before tax | 7,055M | 9,488M | 15,359M | 5,963M | 9,067M |
| Net income | 4,588M | 6,592M | 11,031M | 4,796M | 8,069M |
| EBITDA | 13,406M | 20,265M | 24,200M | 17,091M | 22,179M |
| Diluted EPS | 81.47 | 110.13 | 184.01 | 84.08 | 142.92 |
| Dividends Per Share | 24.75 | 26.60 | 30 | 30 | 30 |
| Total Assets | 129,130M | 139,834M | 161,128M | 268,900M | 278,364M |
| Total liabilities | 62,935M | 65,347M | 78,531M | 185,725M | 190,819M |
| Total equity | 66,195M | 74,487M | 82,597M | 83,171M | 87,542M |
| Operating cash flow | 5,546M | 21,179M | 7,097M | -4,076M | 18,925M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 1,034.44M | 1,156.24M | 1,195.10M | 1,378.39M | 1,486.18M |
| Gross Profit | 393.81M | 426.70M | 443.96M | 347.32M | 368.15M |
| Operating income | 73.70M | 87.55M | 107.50M | 92.58M | 119.09M |
| Income before tax | 70.42M | 86.36M | 127.90M | 55.06M | 81.80M |
| Net income | 45.80M | 60.00M | 91.86M | 44.28M | 72.80M |
| EBITDA | 133.83M | 184.46M | 201.52M | 157.82M | 200.11M |
| Diluted EPS | 0.81 | 1.00 | 1.53 | 0.77 | 1.28 |
| Dividends Per Share | 0.24 | 0.24 | 0.24 | 0.27 | 0.27 |
| Total Assets | 1,253.87M | 1,166.01M | 1,433.58M | 2,413.17M | 2,617.43M |
| Total liabilities | 611.10M | 544.89M | 698.70M | 1,666.74M | 1,794.25M |
| Total equity | 642.76M | 621.11M | 734.88M | 746.39M | 823.14M |
| Operating cash flow | 55.36M | 192.78M | 59.10M | -37.64M | 170.75M |
Valuation Measures
| Mar 2018 | |
| PER | 11.69 |
| ROA | 2.94% |
| ROE | 9.45% |
| Operating margin | 8.01% |
| Profit margin | 4.89% |
Key executives
- President & Representative Director: Yuichi Tamura
- Director, Senior Head-Compliance & Internal Audit: Kenji Akane
- Director & General Manager-Administration: Noboru Inasaka
- Director & Managing Executive Officer: Takahiro Yoshikawa
- Auditor: Yoshihito Sugi
Shareholders
- TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (13.9%)
- Nichi-Iko Pharmaceutical Co., Ltd. (5.9%)
- Hokuhoku Financial Group, Inc. (4.6%)
- Nipro Corp. (2.1%)
- The Vanguard Group, Inc. (1.7%)
- Nomura Asset Management Co., Ltd. (1.4%)
- Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.3%)
- Medipal Holdings Corp. (1.2%)
- Dimensional Fund Advisors LP (1.1%)
- Nichi-Iko Pharmaceutical Employee Incentive Plan (0.9%)
Contact Details
- Website:http://www.nichiiko.co.jp
- Phone: +81.76.432.2121
Related Companies
- Nichi Iko Pharmaceutical Trust
- Astellas Pharma Tech Co., Ltd. /Fuji Plant Bus/
- Nichi-Iko Pharmaceutical Employee Incentive Plan
- Nichiiko Pharma KK
- Nichiiko Osaka KK
- Yakuhan Pharmaceutical Co., Ltd.
- Sagent Pharmaceuticals, Inc.
- Kobayashi Pharmaceutical Industries Co. Ltd.
- Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
- Oriental Pharmaceutical Co., Ltd.
- Teikoku Medix Co., Ltd.
- Japan Galen, Inc.
- Maruko Pharmaceutical Co. Ltd.
- Nichiiko Pharmaceutical Employee Stock Pwnership Plan
Competitors
- Sawai Pharmaceutical Co., Ltd.
- Fuji Pharma Co., Ltd.
- Towa Pharmaceutical Co., Ltd.
- Aceto Corporation
- Hikma Pharmaceuticals Plc
- Spectrum Pharmaceuticals, Inc.
- Amphastar Pharmaceuticals Inc
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.
Last Updated on 20 Jul, 2018You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
Your full access to the Nikkei Asian Review has expired
